uniQure Announces Pricing of its Public Offering
October 24 2017 - 8:14PM
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company
advancing transformative therapies for patients with severe unmet
medical needs, such as hemophilia B, Huntington’s disease and
congestive heart failure, today announced the pricing of its
underwritten public offering of 5,000,000 of its ordinary shares at
a public offering price of $18.25 per share. The gross proceeds to
uniQure from the offering, before deducting the underwriting
discounts and commissions and estimated offering expenses payable
by uniQure, are expected to be $91,250,000. All ordinary shares to
be sold in the offering are being sold by uniQure. In addition,
uniQure has granted to the underwriters a 30-day option to purchase
up to 750,000 additional ordinary shares at the public offering
price, less underwriting discounts and commissions. The offering is
expected to close on or about October 27, 2017, subject to the
satisfaction of customary closing conditions.
Leerink Partners and Evercore ISI are acting as
joint book-running managers for the offering. Chardan is acting as
lead manager and H.C. Wainwright & Co. is acting as co-manager
for the offering.
The securities described above are being offered by
uniQure pursuant to its shelf registration statement on Form S-3
(File No. 333-216701) filed with the Securities Exchange Commission
(the “SEC”) on March 15, 2017, as amended on May 15, 2017 and
declared effective by the SEC on May 26, 2017. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering was filed with the SEC and a final prospectus supplement
and the accompanying prospectus relating to this offering will be
filed with the SEC. When available, copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may be obtained from Leerink Partners LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, MA 02110, by
telephone at (800) 808-7525 ext. 6132 or by email at
Syndicate@Leerink.com; and Evercore Group L.L.C., Attention: Equity
Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY
10055, or by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com. The preliminary prospectus supplement
and accompanying prospectus is also available, and the final
prospectus supplement and accompanying prospectus will be
available, for free on the SEC’s website at http://www.sec.gov.
This press release shall not constitute an offer to
sell or the solicitation of an offer to buy these securities, nor
shall there be any sale of these securities, in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction. Any offer,
if at all, will be made only by means of the prospectus supplement
and accompanying prospectus forming a part of the effective
registration statement.
About uniQure
uniQure is delivering on the promise of gene
therapy - single treatments with potentially curative results. We
are leveraging our modular and validated gene therapy technology
platform to advance a pipeline of proprietary and partnered gene
therapies to treat patients with hemophilia, Huntington’s disease
and cardiovascular diseases.
Forward-Looking Statement
This press release contains certain statements that
are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements include, without limitation,
statements regarding our expectations of market conditions, the
satisfaction of customary closing conditions related to the public
offering, and other statements including the words “may,” “will,”
“intend,” and similar expressions (as well as other words or
expressions referencing future events, conditions or
circumstances), which constitute and are intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, including: the uncertainties related
to market conditions and the completion of the public offering on
the anticipated terms, or at all, continued interest in our rare
disease portfolio, the ability to develop our product candidates
and technologies, the impact of changes in the financial markets
and global economic conditions, and other risks as are set forth in
uniQure’s Annual Report on Form 10-K and other reports filed by
uniQure with the SEC. uniQure undertakes no obligations to make any
revisions to the forward-looking statements contained in this
release or to update them to reflect events or circumstances
occurring after the date of this release, whether as a result of
new information, future developments or otherwise.
uniQure Contacts
For Investors:
Maria Cantor
Direct : +339-970-7536Mobile:
617-680-9452m.cantor@uniQure.com
Eva M. MulderDirect: +31 20 240
6103Mobile: +31 6 52 33 15 70e.mulder@uniQure.com
For Media:
Tom MaloneDirect:
339-970-7758Mobile: 339-223-8541t.malone@uniqure.com
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024